Ainos, Inc. (NASDAQ:AIMD) shares were better Friday, on highlighting the continued expansion of its Smell AI deployments, powered by AI Nose, across semiconductor, robotics, and healthcare infrastructure, highlighted by recent third-party research published by VASRO GmbH.
The report underscores Smell AI's progression from isolated sensing applications to scalable multi-domain AI perception platform and identifies 2026 as a key scale-up year as Ainos moves toward deployment and repeatable revenue generation.
The report highlights growing visibility into Smell AI's transition from ecosystem development to real-world deployment, with increasing emphasis on converting deployments into repeatable revenue-generating programs across multiple environments.
As part of this expansion, Ainos is initiating deployment of Smell AI within hospital infrastructure through collaboration with MacKay Memorial Hospital and Topco Scientific Co., Ltd. Initial applications focus on environmental monitoring and safety across power and electromechanical systems, HVAC infrastructure, chemical handling environments, and clinical laboratory settings, including MRI facilities.
“According to the report,” this morning’s news release says, “these environments position Smell AI as an early perception layer for otherwise invisible environmental signals, including chemical exposure and airborne germs, supporting improved safety and operational resilience in hospital settings.”
AIMD shares traded at $1.663, up 2.8 cents, or 1.7%, from Thursday.
Tech Insider
